Eli Lilly has placed a 79‑year‑old patient on an expanded‑access protocol for retatrutide, an experimental obesity drug still in Phase III trials. The individual, deemed ineligible for bariatric surgery because of age and comorbidities, received the therapy despite lacking the typical trial‑eligible profile. The notice listing the drug name offers scant detail, prompting suspicion about the patient’s identity and omits monitoring details.

Stat reporters asked the White House and HHS whether former president Donald Trump matches the unnamed patient, noting his recent medical memo omitted obstructive sleep apnea and pulmonary hypertension. White House spokesperson Kush Desai deferred to HHS, while HHS spokeswoman Emily Hilliard reiterated FDA policy that each expanded‑access request is evaluated case‑by‑case publicly review, without confirming or denying Trump’s involvement.

Industry observers flag the move as unusual; expanded use typically covers cohorts with defined clinical criteria, not a single senior patient. Lilly’s spokesperson Misty Fuller declined comment, citing regulatory compliance, and NIH clinician Muniyappa remained silent. This opacity raises fairness concerns for drug allocation.